Previous 10 | Next 10 |
Backed by large clinical validation study with over 650 RhD-negative patients with confirmed outcomes, resulting in 100% sensitivity and >99% specificity Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of a new...
2024-04-24 09:30:00 ET Summary Artisan Partners is an independent investment management firm focused on providing high value-added, active investment strategies to sophisticated clients globally. The portfolio solidly outperformed the MSCI AC World Index. Holdings in health ca...
2024-04-23 09:30:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the quarter ended March 31, 2024, Baron Health Care Fund advanced 8.92% compared wi...
Demonstrates commitment to generating real-world clinical evidence to change disease management and improve patient outcomes Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that it has passed a significant milestone with the...
ProActive study shows Natera’s Prospera Kidney™ test detects rejection five months before biopsy Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced a new publication from the ProActive study in Transplantation supporting ...
Prospective, multi-center Trifecta-Heart and DTRT-2 studies demonstrate excellent performance of the Prospera Heart test for detecting rejection in adults and pediatrics Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of...
2024-04-05 18:30:02 ET Stephens analyst issues BUY recommendation for NTRA on April 5, 2024 05:00PM ET. The previous analyst recommendation was Buy. NTRA was trading at $96.75 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...
2024-04-05 11:30:00 ET Summary There were 24 new analysts in March 2024. Gold, Bitcoin, a Bitcoin proxy pair trade, preferred shares, and a SOTP thesis are all covered. We lead off with some of the most discussed articles from last month, with a few that generated over 100 com...
Shares of Natera, Inc. (NASDAQ: NTRA) traded at a new 52-week high today and are currently trading at $95.17. So far today, approximately 361.85k shares have been exchanged, as compared to an average 30-day volume of 1.38M shares. Natera, Inc., a diagnostics company, develops and commercializ...
2024-04-05 10:00:07 ET Read the full article on Seeking Alpha For further details see: Natera upgraded at Bernstein on gross margin trajectory
News, Short Squeeze, Breakout and More Instantly...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended June 30, 2024, after the market close on Aug. 8, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET...
Study reports high accuracy of Signatera for surveillance of MCC patients, suggests potential to reduce frequency of surveillance imaging Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in the Journal of Clinical Oncolog...
2024-07-23 12:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...